Skip Navigation

JNCI Journal of the National Cancer Institute 1988 80(1):60-63; doi:10.1093/jnci/80.1.60
© 1988 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sosman, J. A.
Right arrow Articles by Sondel, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sosman, J. A.
Right arrow Articles by Sondel, P. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 80, No. 1, 60-63, March 2, 1988
© 1988 Oxford University Press

Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity12

Jeff A. Sosman3, Peter C. Kohler3,4, Jacquelyn Hank3, Karen H. Moore3, Robin Bechhofer3,5, Barry Storer3,5, Paul M. Sondel3,6,7,8,*

3Department of Human Oncology, University of Wisconsin Madison, WI.
4Department of Medicine, Madison General Hospital Madison, WI.
5Department of Statistics, University of Wisconsin
6Department of Pediatrics, University of Wisconsin
7Department of Genetics, University of Wisconsin

*Dr. Sondel, University of Wisconsin Clinical Science Center, 600 Highland Ave., K4/448, Madison, WI 53792.

A phase I trial of repetitive weekly cycles of human recombinant interleukin-2 (IL-2) was performed in 23 patients with metastatic carcinoma. Patients received 4 days of IL-2 each week, followed by 3 days of observation, for 4 consecutive weeks. IL-2 was administered iv at 1.0 or 3.0 x 106 U/m2/day by one of three schedules involving continuous or bolus infusions. All treatment was carried out in a general hospital ward without intensive care unit monitoring or support. Seventeen patients had metastatic renal cell carcinoma; three of these demonstrated measurable (>50% shrinkage) partial responses. This study demonstrates that IL-2 given alone without lymphokine-activated killer cells in this manner can induce antitumor effects with acceptable toxicity. [J Natl Cancer Inst 1988;80:60-63]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. A. Hank, J. Surfus, J. Gan, M. Albertini, M. Lindstrom, J. H. Schiller, K. M. Hotton, M. Khorsand, and P. M. Sondel
Distinct Clinical and Laboratory Activity of Two Recombinant Interleukin-2 Preparations
Clin. Cancer Res., February 1, 1999; 5(2): 281 - 289.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
G. L. Clayman, F. J. Liu, H. E. Savage, D. L. Taylor, P. Lavedan, R. M. Buchsbaum, C. Pellegrino, J. M. Trujillo, G. Young, and S. P. Schantz
Acute-Phase Proteins in Patients With Head and Neck Cancer Treated With Interleukin 2/Interferon Alfa
Arch Otolaryngol Head Neck Surg, January 1, 1992; 118(1): 41 - 48.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.